In a research report published Thursday, Ascendiant Capital analyst Keay Nakae raised the price target from $18 to $20 on Photomedex PHMD and maintained a Strong Buy rating after better than expected Q4 results.
In the report Ascendiant said, "The Company ended the quarter with $62 MM in cash and equivalents compared to $55 MM at the end of Q3, even after spending $5.4 MM to repurchase 418K shares of its stock during the quarter. Management expects Q1 revenue to be at least $57 MM."
On Wednesday, Photomedex closed at $16.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in